Physician profile
Fausto Gonzalez
NPI 1124087713
$12,514.50
in general payments reported to CMS, 2019-2025
46 companies · $1,975 in 2025
The $1,975 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $778 · 2020: $1,391 · 2021: $1,797 · 2022: $2,164 · 2023: $2,580 · 2024: $1,830 · 2025: $1,975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,385.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,851.83 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $1,404.86 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,220.95 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $809.39 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $658.03 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $648.28 | 2022-2025 | |
| Ardelyx, INC. | $553.98 | 2023-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $462.53 | 2020-2025 | Trelegy Ellipta, Shingrix |
| Allergan, INC. | $448.13 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $385.41 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $383.82 | 2019-2024 | Verquvo, Steglatro, Belsomra |
| Amgen INC. | $360.65 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.27 | 2019-2025 | Jardiance, Synjardy |
| Biohaven Pharmaceutical Holding Company LTD. | $288.90 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $275.74 | 2019-2023 | Trintellix |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fausto Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.